An international biotech company focused on innovative drug discovery, precision medicine, cell & gene therapy, regenerative medicine and AI-assisted drug development — advancing validated programs from the laboratory to the clinic.
Our gene and cell therapy platform and small nucleic acid drug platform support a disciplined pipeline focused on oncology and precision therapeutics.
Attenuated Salmonella delivering shSTAT3/shPD-L1 gene therapy directly into the tumor microenvironment — tumor enrichment over 1,000× normal tissue.
Learn more →
mRNA drugs and mRNA vaccines addressing oncogenic drivers and tumor antigens across major solid tumors.
Learn more →
Metabolic-immunotherapy programs targeting GPR81 and regenerative cell therapy programs for high-unmet-need indications.
Learn more →"Where life continues…" — our vision. We build precision therapeutics with technology and responsibility.
Core candidates have completed animal proof-of-concept validation; IND submission is targeted within 12–18 months.
Stage information is presented for informational purposes and subject to confirmation. See our full pipeline.
From our administrative headquarters in New York to R&D, clinical and commercial bases across Asia and Europe.
We are pleased to launch our new corporate website, sharing our science, pipeline and company progress with investors and partners.
Peer-reviewed research supporting our platform technologies will be featured here as they become available.
Details of upcoming scientific conference presentations and investor events will be posted here.
Our team welcomes inquiries from potential partners, investors and researchers.